Medindia

X

Perceptive Informatics Appoints Leading Imaging Expert Dr. Kenneth G. Faulkner to Vice President of Medical Imaging

Monday, July 28, 2008 General News J E 4
Advertisement
BOSTON, July 28 Perceptive Informatics, thetechnology subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), aleading global biopharmaceutical services organization, announced today thatit has appointed Kenneth G. Faulkner, Ph.D., to the position of Vice Presidentof Medical Imaging. Dr. Faulkner, who has 22 years of experience in theapplication of specialized medical imaging techniques in support ofbiopharmaceutical product development, will oversee medical imaging worldwide.

"Biopharmaceutical companies are increasingly using our novel medicalimaging analyses as biomarkers or surrogate endpoints to assess safety andefficacy. Dr. Faulkner's in-depth experience will further strengthenPerceptive Informatics' medical imaging capabilities to help clientsaccelerate decisions about the development of new treatments," said Todd A.Joron, Corporate Vice President and General Manager of Perceptive Informaticsat PAREXEL International.

Dr. Faulkner commented, "Perceptive Informatics is a clear leader in thefield of medical imaging in support of clinical research, especially throughthe combination of its in-depth therapeutic expertise and advanced imagingtechnologies. I am excited to work with this high caliber global team andcontribute my experience to help clients in the design and execution of theirclinical studies across a broad range of therapeutic areas."

Prior to joining PAREXEL, Dr. Faulkner was Vice President of ScientificServices at Synarc, a provider of centralized imaging, molecular markers, andclinical research facilities, which he helped to found in 1998. Previously, hewas Chief Scientist and Director of Marketing and Product Development for theLunar Densitometry business unit of GE Healthcare that is dedicated to bonehealth. Dr. Faulkner received his Ph.D. in Biomedical Engineering from theUniversity of California, Berkeley and San Francisco. Dr. Faulkner holds threepatents related to the use of medical imaging for the assessment ofosteoporosis, and has published over 70 scientific articles in the areas ofosteoporosis diagnosis and treatment. He has served on the Boards of Directorsof the International Society of Clinical Densitometry and Oregon Board ofRadiologic Technology, and has participated as an advisor to the U.S. Food andDrug Administration Center for Devices and Radiological Health (CDRH).

The Perceptive Informatics Medical Imaging Division provides specializedservices for clinical study sponsors who increasingly rely on medical imagingas a surrogate endpoint in assessing the efficacy and safety of new products.Perceptive Informatics radiology experts provide a range of capabilities inthe application of imaging techniques from early clinical development throughperi-approval studies. The medical imaging team operates globally and servicesa wide range of therapeutic areas, including oncology, central nervous system,musculoskeletal, cardiovascular, and metabolism/endocrinology imaging.

About Perceptive Informatics, a PAREXEL Company

PAREXEL's Technology Division, Perceptive Informatics, combines clinicalknowledge, quality and regulatory experience with advanced technology todecrease time to market, risk and cost associated with clinical trials.Perceptive's portfolio includes Medical Imaging, Clinical Trial ManagementSystems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), andIntegration Services as well as web-based portal solutions, tracking tools,electronic diaries and investigator database solutions. Perceptive offersmedical imaging services to rapidly and objectively assess the safety andefficacy of new drugs, biologics and medical devices in clinical trials. TheIMPACT(R) solution is Perceptive's market-leading CTMS product with 26,000users worldwide, and Perceptive's INITIATOR(TM) trial management producttargets the needs of Phase I units. For more information about PerceptiveInformatics
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Vanda Pharmaceuticals Announces Receipt of Not App...
S
SectorWatch.biz Issues MarketStats on Renal and Me...